Clareo Health | Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis
Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Johns Hopkins University
With
Biogen
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
A participant in the ADVANCE study aged 18 to 55 years old, inclusive, at the time of informed consent
You may not be if
As per the ADVANCE main study
History of intraocular surgery, retinal disease, glaucoma, or diabetes
